Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done?

Cell Mol Immunol. 2022 Jan;19(1):122-124. doi: 10.1038/s41423-021-00789-3. Epub 2021 Oct 25.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • China
  • Immunotherapy, Adoptive
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen